V8 Peptides — Engineered Performance
Research Library
TB-500 Research Questions, Answered With Sources
TB-500Guide

TB-500 Research Questions, Answered With Sources

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

TB-500 is the thymosin β4 17–23 fragment; most published biology is about the whole protein. The product page lists it as Ac-LKKTETQ (about 889 Da), matching the doping-control literature. Studies of the protein reported effects in rat wound and ligament models and in cardiac cells, but a 2012 knockout study found it dispensable for heart development, and in mdx mice only one histological endpoint moved. Supplied for laboratory research use only.

Questions about TB-500 tend to arrive in the same order: what is it, how does it relate to thymosin β4, what have studies shown, what do the studies not show, and how is a vial handled? This guide answers them in that order, with each answer tied to a source and with the limits stated. It is a laboratory reference for readers working with the TB-500 research peptide, which V8 Peptides supplies as a 10 mg lyophilized powder with a ≥98% HPLC specification. It makes no claim about use outside the laboratory, and the material is sold for laboratory research use only.

Other guides on this site go deeper on individual topics: the TB-500 research overview, the actin-binding motif and migration assays, the history of TB-500 and thymosin β4 research, and BPC-157 versus TB-500. This one is the short map that connects them.

What is TB-500?

The product page lists TB-500 as the thymosin β4 fragment (17–23), Ac-LKKTETQ, and describes it as the laboratory name for a synthetic peptide based on thymosin β4, a small, highly conserved protein found in nearly all nucleated cells and best known as the main G-actin-sequestering molecule in the cytoplasm. In the equine doping-control literature, a veterinary preparation known as TB-500 is described as containing a synthetic version of LKKTETQ, the segment at positions 17–23 of thymosin β4, with an artificially acetylated N-terminus (Ho and colleagues, 2012). That paper identifies this segment as the active site responsible for actin binding, cell migration and wound healing and reports the claims made for the preparation. It is an analytical paper; it does not test those claims. The product page gives its mass as about 889 Da, and the whole protein has 43 amino acids (Banerjee and colleagues, 2012).

Two practical points follow. The name "TB-500" has been used loosely, so the sequence-confirmation line of your lot certificate matters. And most published biology concerns the whole protein, not the fragment.

What does thymosin β4 do in cells?

A review of its physiology lists reported activities including promotion of cell migration, blood vessel formation and cell survival, stem-cell differentiation, modulation of cytokines, chemokines and proteases, upregulation of matrix molecules and gene expression, and downregulation of a major nuclear transcription factor (Crockford and colleagues, 2010). The same review notes that these properties underlie ongoing and planned clinical studies of the protein. That is context for the research interest, not evidence about a laboratory fragment.

Reported activityWhere it was reportedMolecule tested
Keratinocyte migration and wound re-epithelializationRat full-thickness wound model and Boyden chamber (Malinda and colleagues, 1999)Thymosin β4 protein
Cardiomyocyte migration and survival, Akt activation through ILKEmbryonic heart, cultured cells, mouse coronary ligation (Bock-Marquette and colleagues, 2004)Thymosin β4 protein
Epicardial progenitor outgrowth and vessel developmentMouse mutants and adult epicardial explants (Smart and colleagues, 2007)Thymosin β4 protein
Ligament repairRat medial collateral ligament transection (Xu and colleagues, 2013)Thymosin β4 protein
Actin binding, migration, wound healing (stated as properties of the 17–23 segment)Cited in an equine doping-control paper (Ho and colleagues, 2012)LKKTETQ segment, as a statement of background

The last row is the only one that mentions the fragment, and it is a statement in an analytical paper's introduction.

What did the wound-healing study report?

In a rat full-thickness wound model, thymosin β4 added topically or intraperitoneally increased re-epithelialization by 42% over saline controls at 4 days and by as much as 61% at 7 days; exposed wounds also contracted at least 11% more than controls by day 7, and increased collagen deposition and angiogenesis were observed. In a Boyden chamber assay, keratinocyte migration was stimulated 2–3-fold over medium alone when as little as 10 pg of the protein was added (Malinda and colleagues, 1999). These are the figures most often repeated in popular summaries. The reading to keep in mind is that they come from one protein in one species and one wound type, and the authors describe the protein as a potent wound-healing factor in that model.

What did the ligament study report?

In a rat model, the medial collateral ligament was transected and a fibrin sealant containing 1 µg of thymosin β4 was placed in the gap. At 4 weeks, healing tissue in exposed animals had uniform, evenly spaced fiber bundles, larger collagen fibril diameters, and higher mechanical properties in the healing femur–ligament–tibia complex than controls (Xu and colleagues, 2013). The design, local delivery in a carrier at the lesion, is itself informative: the effect was tested where the protein was applied, not by systemic exposure.

Is thymosin β4 required for the heart?

The answer depends on the paper. The 2007 study identified it as essential for coronary vessel development in mice (Smart and colleagues, 2007). A 2012 study with global and cardiac-specific knockouts reported normal heart and vessel formation and normal adult cardiac function, and concluded the protein is dispensable for those processes (Banerjee and colleagues, 2012). The conflict is examined in a companion article on the thymosin β4 knockout evidence.

Does the evidence show it improves muscle?

A study of chronic thymosin β4 administration in dystrophin-deficient mdx mice, 150 µg twice a week for 6 months with exercise, reported more regenerating fibers in skeletal muscle of exposed mdx mice. It also reported no significant improvement in grip strength, cardiac shortening fraction or fibrosis compared with untreated mdx mice (Spurney and colleagues, 2010). This is a useful correction to the idea that every endpoint moves: one histological marker changed and the functional endpoints did not.

Quick reference: what the sources support

Claim you may readWhat the source supports
"TB-500 is thymosin β4"No. It is described as a fragment-based peptide; the protein has 43 residues
"TB-500 speeds wound healing"The wound data are for the protein, in rats; the fragment's activities were claimed, not tested, in the doping-control paper
"It is required for heart development"Contradicted by a 2012 knockout study
"It repairs muscle"One histological endpoint moved in mdx mice; function did not improve
"It heals ligaments"Local protein delivery improved histology and mechanics in one rat model at 4 weeks

How is a TB-500 vial prepared and stored?

The product page gives the arithmetic: milligrams of peptide divided by milliliters of diluent equals stock concentration, so adding 2 mL to the 10 mg vial gives 5 mg/mL and 1 mL gives 10 mg/mL. Molar concentration is cM = (m / MW) / V, and the calculator confirms any combination. The page advises adding diluent gently down the side of the vial and rotating it slowly, since the powder normally goes into solution within a minute or two without agitation. Lyophilized vials are refrigerated at 2–8 °C on arrival and frozen at −20 °C if they will not be used soon; solutions are kept at 2–8 °C, aliquoted, and not held at room temperature longer than necessary. The general logic, that the dry state is far more stable than solution, is in the stability literature (Manning and colleagues, 2010). Step-by-step guides are in how to reconstitute TB-500 and how to reconstitute a lyophilized peptide.

How should the material be verified?

The product page lists measured purity, identity and sequence confirmation, a batch number and a test date among the contents of a certificate, noting that sequence confirmation is reported where a certificate is published. Match the lot string on the vial to the document on the COA page, and note if none is published. TB-500 purity testing explains the methods, and how to read a COA covers the fields.

What would a sound TB-500 experiment look like?

  1. State the molecule: fragment, protein or unspecified, with the lot certificate in the methods.
  2. Choose a model in which the question is a cell-level or tissue-level one, such as migration, tube formation or scratch closure.
  3. Include a vehicle control and a scrambled or reversed-sequence control peptide with the same N-terminal modification.
  4. Test a concentration series, not a single point.
  5. Use two independent readouts and pre-specify them.
  6. Report negative or null endpoints as the mdx study did.

What is not known

The studies above do not say how the fragment behaves in the same models, whether it reproduces any of the protein's activities, or what a reconstituted stock's stability window is. Where your work needs those answers, the experiment has to provide them.

Related reading

Frequently asked questions

What is TB-500?

The product page lists it as the thymosin β4 17–23 fragment, Ac-LKKTETQ, and a doping-control paper describes the key ingredient of a preparation called TB-500 the same way.

How is TB-500 different from thymosin β4?

Thymosin β4 is a 43-amino-acid protein. The TB-500 ingredient described in the literature is a seven-residue acetylated segment, so protein results cannot be assumed to apply to it.

What did the 1999 wound-healing study report?

In rats, thymosin β4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, with increased collagen deposition and angiogenesis, and stimulated keratinocyte migration in a Boyden chamber assay.

What did the ligament study report?

In rats with a transected medial collateral ligament, thymosin β4 delivered in a fibrin sealant gave better histology, larger collagen fibril diameters and higher mechanical properties at 4 weeks than controls.

Did thymosin β4 improve muscle function in mdx mice?

The 2010 study reported more regenerating fibers but no significant improvement in grip strength, cardiac shortening fraction or fibrosis.

Is thymosin β4 essential for heart development?

A 2007 paper said it was essential for coronary vessel development; a 2012 knockout study reported normal development and adult function and concluded it is dispensable.

How do I make a 5 mg/mL TB-500 stock?

Add 2 mL of diluent to a 10 mg vial, as the product page states, and confirm with the calculator. Use c = m / V.

How is TB-500 stored?

The product page states 2–8 °C on arrival or short term and −20 °C for long term, sealed, dry and out of the light. Reconstituted stock should be kept at 2–8 °C and aliquoted.

Where do I find a TB-500 certificate?

On the COA page, matched by lot number. The product page notes that sequence confirmation is reported on the certificate where one is published.

Is TB-500 from V8 for use in people or animals?

No. It is sold strictly for laboratory research use only.

Related reading: TB-500 Mechanism: When Thymosin β4 Knockouts Disagree, TB-500 Muscle and Ligament Animal Studies: Endpoints, What Is TB-500? Decoding the Name, Sequence and Mass.

References

  1. Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. doi:10.1016/j.chroma.2012.09.043
  2. Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010;1194:179-189. doi:10.1111/j.1749-6632.2010.05492.x
  3. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. doi:10.1046/j.1523-1747.1999.00708.x
  4. Xu B, Yang M, Li Z, et al. Thymosin β4 enhances the healing of medial collateral ligament injury in rat. Regul Pept. 2013;184:1-5. doi:10.1016/j.regpep.2013.03.026
  5. Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. doi:10.1038/nature03000
  6. Smart N, Risebro CA, Melville AA, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. doi:10.1038/nature05383
  7. Banerjee I, Zhang J, Moore-Morris T, et al. Thymosin beta 4 is dispensable for murine cardiac development and function. Circ Res. 2012;110(3):456-464. doi:10.1161/CIRCRESAHA.111.258616
  8. Spurney CF, Cha HJ, Sali A, et al. Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One. 2010;5(1):e8976. doi:10.1371/journal.pone.0008976
  9. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.